Project Name: Northern Trust Pharmacist Led Optimisation Clinic for Heart Failure (HF) Medicines Post Discharge

Project Summary: 

The main objective of the CWP is to improve the quality of care delivered to Heart Failure (“HF”) patients, at the CW Partner’s Trust, in line with National Institute for Clinical Excellence (NICE), and European Society of Cardiology (ESC) guidance. 

This CWP will aim to improve the CW Partner’s current hospital-based specialist HF Service through the deployment of a 0.4 FTE Heart Failure Band 8A Pharmacist (who will move from a part time contract to work extra days as additional resource for HF Medicines), for the duration of 12 months. The intention is to substantiate the roles to carry on with the service through the development and submission of a Business Case as part of the milestone delivery

Expected Benefits: 

Anticipated benefits for patients 

  • Improved access to evidence-based treatment.
  • A more equitable and consistent care and access to care.
  • An enhanced experience for patients, and their carers, who live with HF.
  • Increased access to education on heart failure will enable patients to self-manage their condition.
  • A personalised HF care plan will help the patient to self-manage their condition.

Anticipated benefits for the organisation 

  • Increase the overall quality of care and improve equity of access to specialist care for patients with HF.
  • Increase proportion of patients with HF being managed in accordance with the ESC 2023 chronic heart failure guidelines.
  • A reduction in waiting list time.

Anticipated benefits for Novartis  

  • Further opportunities for the appropriate use of cardiology licensed medicines in line with NICE guidelines1, including Novartis’s medicine.
  • Improved reputation.
  • Improved professional and transparent relationship and Health Board between Novartis and the NHS

Start Date & Duration: October 2025, 18 months (12 months clinical activity)

FA-11545196 | October 2025